| Literature DB >> 30056425 |
Paola Piscopo1, Margherita Grasso2, Maria Puopolo1, Emanuela D'Acunto1,3, Giuseppina Talarico4, Alessio Crestini1, Marina Gasparini4, Rosa Campopiano5, Stefano Gambardella5, Anna Elisa Castellano5, Giuseppe Bruno4, Michela A Denti2, Annamaria Confaloni1.
Abstract
Given the heterogeneous nature of frontotemporal dementia (FTD), sensitive biomarkers are greatly needed for the accurate diagnosis of this neurodegenerative disorder. Circulating miRNAs have been reported as promising biomarkers for neurodegenerative disorders and processes affecting the central nervous system, especially in aging. The objective of the study was to evaluate if some circulating miRNAs linked with apoptosis (miR-29b-3p, miR-34a-5p, miR-16-5p, miR-17-5p, miR-107, miR-19b-3p, let-7b-5p, miR-26b-5p, and 127-3p) were able to distinguish between FTD patients and healthy controls. For this study, we enrolled 127 subjects, including 54 patients with FTD, 20 patients with Alzheimer's disease (AD), and 53 healthy controls. The qRT-PCR analysis showed a downregulation of miR-127-3p in FTD compared to controls, while the levels of other miRNAs remained unchanged. Then, miR-127-3p expression was also analyzed in AD patients, finding a different expression between two patient groups. A receiver operating characteristic curve was then created for miR-127-3p to discriminate FTD versus AD (AUC: 0.8986), and versus healthy controls (AUC: 0.8057). In conclusion, miR-127-3p could help to diagnose FTD and to distinguish it from AD.Entities:
Keywords: Biomarker; differential diagnosis; frontotemporal dementia; miR-127-3p; miRNA
Mesh:
Substances:
Year: 2018 PMID: 30056425 DOI: 10.3233/JAD-180364
Source DB: PubMed Journal: J Alzheimers Dis ISSN: 1387-2877 Impact factor: 4.472